SCHEDULE 13D/A: Vedanta Entities Update Stake in Reviva Pharmaceuticals, Parag Saxena Maintains 12.4% Beneficial Ownership

Vedanta Management entities, including Parag Saxena, have filed an Amendment No. 9 to their Schedule 13D, detailing updated beneficial ownership percentages in Reviva Pharmaceuticals Holdings, Inc., with some entities falling below the 5% threshold.

Summary

• This document is Amendment No. 9 to the Schedule 13D filing for Reviva Pharmaceuticals Holdings, Inc. (the "Issuer").
• The filing updates the beneficial ownership of Common Stock by Parag Saxena and associated Vedanta entities, based on 46,602,699 outstanding shares as of January 30, 2025.
• As of the filing date (January 31, 2025), Parag Saxena beneficially owns 6,268,906 shares, representing 12.4% of the Issuer's Common Stock.
• Vedanta Partners, LLC beneficially owns 5,376,169 shares, or 10.6% of the outstanding Common Stock.
• Vedanta Associates, L.P. beneficially owns 3,408,401 shares, or 6.9% of the outstanding Common Stock.
• Vedanta Associates-R, L.P. beneficially owns 1,967,768 shares, or 4.1% of the outstanding Common Stock, and ceased to be a beneficial holder of more than 5% on December 18, 2024.
• Beta Operators Fund, L.P. beneficially owns 2,138,130 shares, or 4.4% of the outstanding Common Stock, and also ceased to be a beneficial holder of more than 5% on December 18, 2024.
• The beneficial ownership calculations include shares held directly, as well as shares underlying warrants and pre-funded warrants exercisable within 60 days.
• Certain warrants held by Vedanta Associates-R and Beta Operators are subject to a 4.99% issuance limitation, prohibiting exercise to the extent that beneficial ownership would exceed this threshold.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While two entities dropped below 5% ownership, the primary beneficial owner, Parag Saxena, maintains a substantial stake, and the filing is a routine update of ownership structure rather than a negative event.

Positives

• Parag Saxena, a director of Reviva Pharmaceuticals, maintains a significant beneficial ownership stake of 12.4%, indicating continued alignment with shareholder interests and confidence in the company.
• The detailed breakdown of holdings, including shares, warrants, and pre-funded warrants, provides comprehensive transparency regarding the full extent of the reporting persons' potential ownership.

Negatives

• Two reporting entities, Vedanta Associates-R, L.P. and Beta Operators Fund, L.P., have reduced their beneficial ownership below the 5% threshold, which could be interpreted as a slight reduction in direct commitment from these specific funds.

Risks

• Warrants held by certain reporting persons contain an issuance limitation (the "Blocker") that prohibits exercise if it results in beneficial ownership exceeding 4.99%, which could restrict the full conversion of these instruments into common stock and potentially impact future liquidity or control dynamics.

Future Outlook

The document does not provide forward-looking statements or guidance regarding the company's operations or financial performance, focusing solely on beneficial ownership changes.

Industry Context

This Schedule 13D amendment is a routine disclosure of changes in significant beneficial ownership and does not provide information related to broader industry trends or competitive landscape for Reviva Pharmaceuticals.

Comparison to Industry Standards

• This document is a regulatory filing detailing beneficial ownership and does not contain information suitable for comparison to industry-specific operational or financial benchmarks.

Stakeholder Impact

• Shareholders: Provides transparency on significant ownership stakes and changes, which can influence investor perception and potential control dynamics.
• Management: The continued significant stake by Parag Saxena, a director, suggests alignment with management's long-term vision.

Next Steps

• The document does not explicitly mention future actions or milestones for the company or the reporting persons beyond the ongoing compliance with SEC filing requirements.

Key Dates

Keywords

REVIVA PHARMACEUTICALS HOLDINGS INC, RVPH, Schedule 13D, Beneficial Ownership, Parag Saxena, Vedanta Management, Common Stock, Warrants, Pre-funded Warrants, SEC Filing, Shareholder Stake